ProPhase Labs Inc is a drug manufacturers-specialty & generic business based in the US. ProPhase Labs shares (PRPH) are listed on the NASDAQ and all prices are listed in US Dollars. ProPhase Labs employs 129 staff and has a trailing 12-month revenue of around $131.3 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $10.16 |
|---|---|
| 52-week range | $4.53 - $15.25 |
| 50-day moving average | $11.31 |
| 200-day moving average | $8.95 |
| Wall St. target price | $11.67 |
| PE ratio | 6.8649 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.48 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.16 from 2022-09-23
| 1 week (2022-09-19) | -6.19% |
|---|---|
| 1 month (2022-08-26) | -16.79% |
| 3 months (2022-06-24) | -13.38% |
| 6 months (2022-03-22) | N/A |
| 1 year (2021-09-24) | 100.00% |
|---|---|
| 2 years (2020-09-25) | 165.27% |
| 3 years (2019-09-25) | 408.00% |
| 5 years (2017-09-26) | 372.56% |
Valuing ProPhase Labs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ProPhase Labs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ProPhase Labs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, ProPhase Labs shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
ProPhase Labs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $41.4 million.
The EBITDA is a measure of a ProPhase Labs's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $131.3 million |
|---|---|
| Operating margin TTM | 28.01% |
| Gross profit TTM | $42 million |
| Return on assets TTM | 26.37% |
| Return on equity TTM | 45.82% |
| Profit margin | 20.23% |
| Book value | $4.34 |
| Market capitalisation | $162.6 million |
TTM: trailing 12 months
Dividend payout ratio: 35.93% of net profits
Recently ProPhase Labs has paid out, on average, around 35.93% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 13.16% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ProPhase Labs shareholders could enjoy a 13.16% return on their shares, in the form of dividend payments. In ProPhase Labs's case, that would currently equate to about $0 per share.
While ProPhase Labs's payout ratio might seem fairly standard, it's worth remembering that ProPhase Labs may be investing much of the rest of its net profits in future growth.
ProPhase Labs's most recent dividend payout was on 2 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 23 May 2022 (the "ex-dividend date").
ProPhase Labs's shares were split on a 2:1 basis on 22 January 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ProPhase Labs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ProPhase Labs shares which in turn could have impacted ProPhase Labs's share price.
Over the last 12 months, ProPhase Labs's shares have ranged in value from as little as $4.5346 up to $15.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProPhase Labs's is -0.4195. This would suggest that ProPhase Labs's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ProPhase Labs has bucked the trend.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.